Turtle Cameron, CEO, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 2191.000000 shares for an estimated $69651.89. Reported holdings after the transaction were 672007.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate p…
within the range.
Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to
0 other filings
0 recent txs